Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of a platinum-based drug plus pemetrexed, leading to an overall survival of approximately 12 months. The dramatic therapeutic scenario of PM has recently changed with the entry into the clinic of immune checkpoint inhibition, which has proven to be an effective approach to improve the survival of PM patients. The aim of the present review is to provide a comprehensive overview of the most promising immunotherapeutic-based strategies currently under investigation for advanced PM.
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream / Calabrò, Luana; Bronte, Giuseppe; Grosso, Federica; Cerbone, Luigi; Delmonte, Angelo; Nicolini, Fabio; Mazza, Massimiliano; Di Giacomo, Anna Maria; Covre, Alessia; Lofiego, Maria Fortunata; Crinò, Lucio; Maio, Michele. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 14:(2024). [10.3389/fimmu.2023.1333661]
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream
Bronte, Giuseppe;
2024-01-01
Abstract
Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of a platinum-based drug plus pemetrexed, leading to an overall survival of approximately 12 months. The dramatic therapeutic scenario of PM has recently changed with the entry into the clinic of immune checkpoint inhibition, which has proven to be an effective approach to improve the survival of PM patients. The aim of the present review is to provide a comprehensive overview of the most promising immunotherapeutic-based strategies currently under investigation for advanced PM.File | Dimensione | Formato | |
---|---|---|---|
Calabrò L - Front Immunol 2024.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso:
Creative commons
Dimensione
1.08 MB
Formato
Adobe PDF
|
1.08 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.